3 IPO Stocks That You Want to Own
Three Motley Fool contributors have joined this roundtable to scour the market for some exciting initial public offerings (IPOs) in the healthcare field. The trio likes Amylyx Pharmaceuticals (NASDAQ: AMLX), a biotech with a treatment for Lou Gehrig's disease; HilleVax (NASDAQ: HLVX), a recent spinout from a Japanese pharmaceutical giant; and DocGo (NASDAQ: DCGO), a busted special purpose acquisition company (SPAC) from 2021 that's already making money.
Here's why our roundtable is excited about these three names.
Alex Carchidi (Amylyx Pharmaceuticals): Amylyx is worth owning because there's a solid chance it'll soon commercialize the first treatment for amyotrophic lateral sclerosis (ALS) that prolongs survival time while also slowing the disease's progression. Its medicine, AMX0035, has been approved for sale in Canada since late July, and regulators at the U.S. Food and Drug Administration will weigh in on the company's application for commercialization on Sept. 29. It's also in the final stages of preparing to launch the drug in the European Union, pending the green light from regulators, which could come in the first half of 2023.
Source Fool.com
